Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025Building on ...
The Motley Fool on MSN6d
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...
Viking Therapeutics (NASDAQ:VKTX), currently trading at $32.65, remained in focus as H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating with a price target of $102.00. According to ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback